A proper clinical evaluation of patients with Multiple Sclerosis (MS) is of great importance to
detect MS progression. It provides important data for physicians on their daily practice as …

Background Multiple sclerosis has both high healthcare and social impacts. Objective The
purpose of this article is to analyse the available literature describing the economic burden …

Background Ocrelizumab was approved for the treatment of relapsing multiple sclerosis
(RMS) and primary progressive multiple sclerosis (PPMS) by the US Food and Drug …

BACKGROUND AND PURPOSE: Synthetic MR imaging enables the creation of various
contrast-weighted images including double inversion recovery and phase-sensitive …

Therapies that target the underlying pathology of multiple sclerosis (MS), including focal and
diffuse damage, may improve long-term disease control. Focal damage (inflammatory …

Background Fingolimod was approved in 2010 for the treatment of patients with the
relapsing‐remitting (RR) form of multiple sclerosis (MS). It was designed to reduce the …

Background Currently, 19 disease-modifying therapies (DMTs) have been approved for the
treatment of patients with relapsing forms of multiple sclerosis (RMS). Objective The …

Accumulating neurological disability has a substantial impact on the lives of patients with
multiple sclerosis (MS). As well as the established Expanded Disability Status Scale (EDSS) …

Abstract Background People with Relapsing-Remitting Multiple Sclerosis (pwRR-MS), may
be affected by subclinical gait impairment. The Expanded Disability Status Scale, the most …

Multiple Sclerosis (MS) is a neurological disease that affects the central nervous system
(CNS). The diagnosis of the disease is quite challenging due to its variation among patients …